Skull Dosimetry for Mitigating Acute Hematologic Toxicity in Patiënten met Non-small Cell Longkanker With Hersenmetastasen Undergoing Cranial Radiotherapie and Immunotherapy

Brain radiation therapy (RT) combined with immunotherapy is standard for patients with non-small cell lung cancer (NSCLC) with brain metastases. However, RT-induced hematologic toxicities (HTs) can cause treatment interruption and lymphopenia, potentially impairing immunotherapy efficacy. Because the skull bone marrow has recently been identified as a key hematopoietic site, this study evaluated the impact of skull RT dose on HTs in patients with NSCLC undergoing cranial RT and immunotherapy.